Common diabetes drug may shield kidneys from chemo damage
NCT ID NCT07018622
First seen Mar 13, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney injury caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for three days around their chemo infusion. Researchers will measure a kidney damage marker (KIM-1) in urine to see if the drug offers protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
RECRUITINGMéxico, Tlalpan, 14080, Mexico
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (a diabetes drug that helps protect kidneys)
What this could lead to
If it works, this could point toward a simple way to prevent kidney damage during chemotherapy, helping patients complete their cancer treatment without delays.
What could go wrong
This is a small, early-phase trial (46 people) testing a biomarker, not a proven outcome. The drug may not reduce kidney injury, and side effects like dehydration or electrolyte imbalances are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.